Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Computer Design Yields Better, More Efficient Therapeutic for Preventing Tissue Damage

26.08.2003


The tedious laboratory trial-and-error method for refining protein/peptide-based medicines could be accelerated and complemented by an innovative in silico (on computer) protein design method, according to researchers at Princeton University, the University of Pennsylvania School of Medicine, and the University of California at Riverside.



Their findings, appearing in a recent issue of the Journal of the American Chemical Society, could drastically decrease the time it takes to move potential biopharmaceuticals from the drawing board to the drug store. In this study, the researchers modeled a peptide (a chain of amino acids, such as a protein or protein fragment) called Compstatin, which prevents the autoimmune-mediated damage of organs during transplantation, and various inflammatory diseases. The computer modeling and optimization process cut down on trial and error and created a version of Compstatin seven times more efficient and stable than the original.

Since the function of a peptide depends on its form, the researchers modeled the effects of substituting each of Compstatin’s 13 amino acid subunits with a different amino acid. The novel in silico sequence design method could then model how the altered amino acid sequence folds together in comparison to the original peptide.


"It is a major challenge to design new peptides and proteins that exhibit the desired function such as improved inhibition for the complement system. The challenge centers around the problem of selecting promising sequences from the huge number of possible combinations and making sure those sequences will have the desired three-dimensional structure," said Christodoulos A. Floudas, PhD, a Professor of Chemical Engineering at Princeton University, whose laboratory developed the in silico de novo protein design approach. "At the heart of this innovative technology is a unique two-stage computer protein design method that not only selects and ranks sequences for a particular fold, but also validates the stability and specificity of the fold for these selected sequences."

"It would have taken us months - or even years - to synthesize and screen the 80 quadrillion possible peptide sequences that the protein design program considered," John D. Lambris, PhD, a professor in Penn’s Department of Pathology & Laboratory Medicine and a co-author on the study whose laboratory had discovered Compstatin in 1996. "In the end, we came up with two analogues to Compstatin - each created by altering one amino acid - that performed its job even better than the original protein."

Compstatin works by blocking human complement, the immune system’s passive alarm network that detects pathogens in the blood. Unfortunately, complement can also attack healthy tissue, and a variety of diseases are associated with complement gone awry, such as multiple sclerosis and hemolytic anemia. In addition, complement is thought to play a role in the destruction of cells during strokes, heart attacks, and burn injuries. The complement reaction is actually a series of interlocking cascades, or chain reactions, of biochemical events involving at least 30 proteins. Compstatin works by preventing the activation of C3, a protein that functions at the point where all the complement protein cascades intersect.

The two Compstatin analogues derived from the experiment are superior in their ability to cling to and, hence, prevent the activation of the C3 complement protein. Based on these two analogs, more Compstatin analogs have since been designed, some of which are 200 fold more active that the original Compstatin, according to Lambris. These new Compstatin analogs will be further refined and tested until ready for clinical trials.

To create templates of the desired shape for Compstatin, Dimitrios Morikis, PhD, a researcher at the Department of Chemical and Environmental Engineering of University of California, Riverside, identified the three-dimensional structure of Compstatin in solution via nuclear magnetic resonance (NMR) experiments, which he then computationally refined.

The computational de novo protein design system, developed at Princeton University by Floudas and postdoctoral associate John Klepeis, is a technological advance made possible by (i) a novel mixed-integer optimization model that narrows 200 trillion amino acid sequences into a short list of candidates that are likely to produce a peptide of the desired shape, and (ii) a system called ASTRO-FOLD that, using first-principles, predicts the structures that would be formed by the candidate sequences. The second step confirms and refines the first.

A distributed computing environment consisting of eighty Linux-based computers was used for all the computational predictions, and the predicted new peptides were subsequently synthesized and experimentally validated in the Lambris laboratory at Penn.

Greg Lester | University of Pennsylvania
Further information:
http://www.uphs.upenn.edu/news/News_Releases/august03/computer.htm

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>